| [25] |
Fan L，Li J，Zhang H，et al.Machine learning analysis for the noninvasive prediction of lymphovascular invasion in gastric cancer using PET/CT and enhanced CT-based radiomics and clinical variables[J]. Abdom Radiol (NY)，2022，47(4)：1209-1222.
|
| [26] |
Findlay JM，Antonowicz S，Segaran A，et al.Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery[J]．Eur Radiol，2019，29(5): 2490-2498.
|
| [27] |
Perlaza P，Ortín J，Pagès M，et al.Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? [J]．Clin Nucl Med，2018，43(6)：402-410.
|
| [28] |
Baek JH，Park DJ，Kim GY，et al.Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer[J]．Anticancer Res, 2019，39(12)：6973-6979.
|
| [29] |
Cao W，Xing H，Li Y，et al.Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy[J]．Biomark Res，2022, 10(1)：38.
|
| [30] |
Rohde C，Yamaguchi R，Mukhina S，et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma[J]．Jpn J Clin Oncol，2019，49(9): 870-876.
|
| [1] |
Wang S，Qi C，Ding J，et al.First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection[J]. Eur J Nucl Med Mol Imaging，2023，50(9)：2802-2817.
|
| [2] |
Sato Y，Okamoto K，Kawano Y，et al.Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives[J]．J Clin Med，2023，12(14)：4646.
|
| [3] |
Jiang H，Shi Z，Wang P，et al.Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer[J]．J Natl Cancer Inst，2019，111(4)：409-418.
|
| [4] |
Qi C，Gong J，Li J，et al.Claudin18.2-specific CAR T cells in gastrointestinal cancers：phase 1 trial interim results[J]．Nat Med，2022, 28(6)：1189-1198.
|
| [5] |
Entezam M，Sanaei MJ，Mirzaei Y，et al.Current progress and challenges of immunotherapy in gastric cancer：A focus on CAR-T cells therapeutic approach[J]．Life Sci，2023，318：121459.
|
| [6] |
Zhao C，Rong Z，Ding J，et al.Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery[J]．Mol Pharm，2022，19(10)：3530-3541.
|
| [7] |
Hu G，Zhu W，Liu Y，et al.Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer：a preclinical study[J]．Eur J Nucl Med Mol Imaging，2022，49(8)：2634-2644.
|
| [8] |
Smyth EC，Nilsson M，Grabsch HI，et al. Gastric cancer[J]．Lancet, 2020，396(10251)：635-648.
|
| [9] |
Machlowska J，Baj J，Sitarz M，et al.Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies[J]．Int J Mol Sci，2020，21(11)：4012.
|
| [10] |
Kinami S，Nakamura N，Tomita Y，et al.Precision surgical approach with lymph-node dissection in early gastric cancer[J]．World J Gastroenterol，2019，25(14)：1640-1652.
|
| [11] |
Hiramatsu Y，Takeuchi H，Goto O，et al.Minimally Invasive Function-Preserving Gastrectomy with Sentinel Node Biopsy for Early Gastric Cancer[J]．Digestion.
|
| [12] |
Linghu E．A new stage of surgical treatment: super minimally invasive surgery[J]．Chin Med J (Engl)，2022，135(1)：1-3.
|
| [13] |
Liu Q，Ding L，Qiu X，et al.Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer：A systematic review and meta-analysis[J]．Int J Surg，2020，73(1)：28-41.
|
| [14] |
Song WC，Qiao XL，Gao XZ.A comparison of endoscopic submucosal dissection (ESD) and radical surgery for early gastric cancer: a retrospective study[J]．World J Surg Oncol，2015，13(1)：309.
|
| [15] |
Quero G，Fiorillo C，Longo F，et al.Propensity score-matched comparison of short- and long-term outcomes between surgery and endoscopic submucosal dissection (ESD) for intestinal type early gastric cancer (EGC) of the middle and lower third of the stomach: a European tertiary referral center experience[J]．Surg Endosc，2021，35(6)：2592-2600.
|
| [16] |
Park KB，Jeon CH，Seo HS，et al.Operative safety of curative gastrectomy after endoscopic submucosal dissection (ESD) for early gastric cancer - 1：2 propensity score matching analysis: A retrospective single-center study (cohort study) [J]．Int J Surg，2020，80(1)：124-128.
|
| [17] |
Fujishiro M，Yoshida S，Matsuda R, et al.Updated evidence on endoscopic resection of early gastric cancer from Japan[J]．Gastric Cancer, 2017，20(Suppl 1)：39-44.
|
| [18] |
Lee GH，Lee E，Park B，et al.Long-term outcomes of endoscopic submucosal dissection and surgery for undifferentiated intramucosal gastric cancer regardless of size[J]．World J Gastroenterol，2022，28(8): 840 -852.
|
| [19] |
Chu YN，Yu YN，Jing X，et al.Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer[J]．World J Gastroenterol，2019，25(35)：5344-5355.
|
| [20] |
Akiyama Y，Katai H，Kitabayashi R，et al.Frequency of lymph node metastasis according to tumor location in clinical T1 early gastric cancer: supplementary analysis of the Japan Clinical Oncology Group study (JCOG0912) [J]. J Gastroenterol，2023，58(6)：519-526.
|
| [21] |
Hanada Y，Choi AY，Hwang JH，et al.Low Frequency of Lymph Node Metastases in Patients in the United States With Early-stage Gastric Cancers That Fulfill Japanese Endoscopic Resection Criteria[J]．Clin Gastroenterol Hepatol，2019，17(9)：1763-1769.
|
| [22] |
Duan K，Li D，Shi D，et al.Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer[J]．Can J Gastroenterol Hepatol，2022，2022：3421078.
|
| [23] |
Hatta W，Gotoda T，Koike T，et al.History and future perspectives in Japanese guidelines for endoscopic resection of early gastric cancer[J]. Dig Endosc，2020，32(2)：180-190.
|
| [24] |
Sekiguchi M，Suzuki H，Oda I，et al.Risk of recurrent gastric cancer after endoscopic resection with a positive lateral margin[J]．Endoscopy, 2014，46(4)：273-278.
|